Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside

Remdesivir, a monophosphate prodrug of nucleoside analog GS-441524, is widely used for the treatment of moderate to severe COVID-19. It has been suggested to use GS-441524 instead of remdesivir in the clinic and in new inhalation formulations. Thus, we compared the anti-SARS-CoV-2 activity of remdes...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Sijia, Zandi, Keivan, Bassit, Leda, Ong, Yee Tsuey, Verma, Kiran, Liu, Peng, Downs-Bowen, Jessica A., McBrayer, Tamara, LeCher, Julia C., Kohler, James J., Tedbury, Philip R., Kim, Baek, Amblard, Franck, Sarafianos, Stefan G., Schinazi, Raymond F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
COVID-19 therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357487/
https://www.ncbi.nlm.nih.gov/pubmed/34870151
http://dx.doi.org/10.1016/j.crphar.2021.100045
Descripción
Sumario:Remdesivir, a monophosphate prodrug of nucleoside analog GS-441524, is widely used for the treatment of moderate to severe COVID-19. It has been suggested to use GS-441524 instead of remdesivir in the clinic and in new inhalation formulations. Thus, we compared the anti-SARS-CoV-2 activity of remdesivir and GS-441524 in Vero E6, Vero CCL-81, Calu-3, Caco-2 ​cells, and anti-HCoV-OC43 activity in Huh-7 ​cells. We also compared the cellular pharmacology of these two compounds in Vero E6, Vero CCL-81, Calu-3, Caco-2, Huh-7, 293T, BHK-21, 3T3 and human airway epithelial (HAE) cells. Overall, remdesivir exhibited greater potency and superior intracellular metabolism than GS-441524 except in Vero E6 and Vero CCL-81 ​cells.

Ejemplares similares